Bioactivity:

BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.

CAS nr:

2414572-47-5

Purity:

98%

Molecular Weight:

561,03

SMILES:

C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)OCCN5CCOCC5

Formula:

C29H29ClN6O4

Pathway:

Tyrosine Kinase/Adaptors,Angiogenesis,JAK/STAT signaling,Angiogenesis,Tyrosine Kinase/Adaptors,Angiogenesis,JAK/STAT signaling,Tyrosine Kinase/Adaptors,NF-_b,Apoptosis

Target:

HER,HER,HER,BTK,BTK,EGFR,EGFR,EGFR,RIP kinase,RIP kinase